Formulations et méthodes pour traiter la rectocolite hémorragique

Formulations and methods for treating ulcerative colitis

Abstract

This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.
La présente invention concerne une composition et des méthodes pour prévenir, traiter ou soulager un symptôme de la rectocolite hémorragique, consistant à administrer à un patient du dolcanatide.

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (96)

    Publication numberPublication dateAssigneeTitle
    WO-2005063206-A1July 14, 2005Alza CorporationMethods and dosage forms for increasing solubility of drug compositions for controlled delivery
    US-5236704-AAugust 17, 1993Sumitomo Pharmaceuticals Co., Ltd.Controlled release formulation
    US-6180608-B1January 30, 2001Praecis Pharmaceuticals, Inc.Pharmaceutical formulations for sustained drug delivery
    WO-03053401-A2July 03, 2003Alza CorporationPreparation et forme posologique pour l'augmentation de la biodisponibilite buccale de macromolecules hydrophiles
    WO-9726015-A1July 24, 1997DelabFormulations de medicaments a liberation continue
    US-6086918-AJuly 11, 2000Unigene Laboratories, Inc.Oral peptide pharmaceutical products
    US-5445832-AAugust 29, 1995Debio Recherche Pharmaceutique S.A.Process for the preparation of microspheres made of a biodegradable polymeric material
    US-5612052-AMarch 18, 1997Poly-Med, Inc.Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
    US-5877224-AMarch 02, 1999Rutgers, The State University Of New JerseyPolymeric drug formulations
    US-5866619-AFebruary 02, 1999Perio Products Ltd., Yissum Research Development Company Of The Hebrew University Of JerusalemColonic drug delivery system
    US-5972389-AOctober 26, 1999Depomed, Inc.Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
    US-6403130-B2June 11, 2002Kiwitech Limited, University Of OtagoHigh-methoxyl pectin-acid casein polymer and process of making
    US-3773919-ANovember 20, 1973Du PontPolylactide-drug mixtures
    US-5952314-ASeptember 14, 1999Demichele; Stephen Joseph, Garleb; Keith Allen, Mcewen; John William, Fuller; Martha KayNutritional product for a person having ulcerative colitis
    WO-9324150-A1December 09, 1993Zeneca LimitedSalts of peptides with carboxy-terminated polyesters
    US-6011011-AJanuary 04, 2000Pharmacia & Upjohn CompanySustained-release protein formulations
    WO-2008151257-A2December 11, 2008Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
    US-5893985-AApril 13, 1999The Lincoln Electric CompanyPlasma arc torch
    WO-03035029-A1May 01, 2003Depomed, Inc.Formulation d'une forme posologique erodable a administration orale et a retention gastrique utilisant des donnees d'essai de desintegration in vitro
    US-5007790-AApril 16, 1991Depomed Systems, Inc.Sustained-release oral drug dosage form
    WO-0174175-A1October 11, 2001Australian Food Industry Science Centre, Commonwealth Scientific & Industrial Research OrganisationEncapsulation d'ingredients alimentaires
    US-4522811-AJune 11, 1985Syntex (U.S.A.) Inc.Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
    US-6620422-B1September 16, 2003Mediolanum Farmaceutici S.P.A.Compositions containing a peptide and polylactic-glycolic acid suitable for preparing subcutaneous implants with an extended release period
    WO-9406452-A1March 31, 1994The Upjohn CompanySustained-release protein formulations
    WO-9415587-A2July 21, 1994Kinerton LimitedConjugues moleculaires ioniques de polyesters biodegradables et de polypeptides biologiquement actifs
    WO-2004064769-A2August 05, 2004Hector HerreraMethodes de production et d'utilisation d'agents d'administration topique
    WO-9740085-A2October 30, 1997Kinerton LimitedAcidic polylactic polymers
    US-5840860-ANovember 24, 1998Commonwealth Scientific And Industrial Research OrganizationFatty acid delivery system comprising a hydrolyzable bond
    EP-0326151-A2August 02, 1989Sumitomo Pharmaceuticals Company, Limited, Koken Co. Ltd.Verbesserte Formulierungen mit kontrollierter Abgabe
    WO-03086297-A2October 23, 2003Lavipharm Laboratories, Inc.Dispositif mucoadhesif multicouche d'administration de medicaments presentant une couche de liberation par eclatement
    WO-9001329-A1February 22, 1990Kanji TakadaEnteric formulations of physiologically active peptides and proteins
    US-5912014-AJune 15, 1999Unigene Laboratories, Inc.Oral salmon calcitonin pharmaceutical products
    US-2014287002-A1September 25, 2014Synergy Pharmaceuticals Inc.Agonists Of Guanylate Cyclase And Their Uses
    US-6309633-B1October 30, 2001Nobex CorporationAmphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
    US-5922356-AJuly 13, 1999Sumitomo Pharmaceuticals Company, Limited, Koken Co., Ltd.Sustained release formulation
    US-6667060-B1December 23, 2003Janssen Pharmaceutica N.V.Pregelatinized starch in a controlled release formulation
    US-4767628-AAugust 30, 1988Imperial Chemical Industries PlcContinuous release pharmaceutical compositions
    WO-2005063156-A1July 14, 2005Shear/Kershman Laboratories, Inc.Systeme d'administration de peptides par voie orale presentant une biodisponibilite amelioree
    WO-2004041195-A2May 21, 2004Supergen, Inc.Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
    WO-2005048998-A1June 02, 2005Commonwealth Scientific & Industrial Research OrganisationSystemes gastro-intestinaux d'administration
    US-6234464-B1May 22, 2001K.D. Pharma Bexbech GmbhMicroencapsulated unsaturated fatty acid or fatty acid compound or mixture of fatty acids and/fatty acid compounds
    US-6368629-B1April 09, 2002Yamanouchi Pharmaceutical Company Ltd.Colon-specific drug release system
    WO-9825642-A2June 18, 1998Praecis Pharmaceuticals IncorporatedPharmaceutical formulations comprising a water-insoluble complex for sustained drug delivery
    US-5968895-AOctober 19, 1999Praecis Pharmaceuticals, Inc.Pharmaceutical formulations for sustained drug delivery
    WO-0149311-A1July 12, 2001Rutgers, The State UniversityFormulation pharmaceutique composee d'un melange polymere et d'un compose actif pour une liberation regulee dans le temps
    WO-9704744-A1February 13, 1997Rutgers, The State University, Emory UniversityFormulations de medicaments polymeres
    US-5672659-ASeptember 30, 1997Kinerton LimitedIonic molecular conjugates of biodegradable polyesters and bioactive polypeptides
    US-5134122-AJuly 28, 1992Debiopharm S.A.Method for preparing a pharmaceutical composition in the form of microparticles
    WO-0101964-A2January 11, 2001Sedum Laboratories, Inc.Ionically formulated biomolecule microcarriers
    WO-2005027878-A1March 31, 2005Penwest Pharmaceuticals Co.Delayed released dosage forms
    US-5980945-ANovember 09, 1999Societe De Conseils De Recherches Et D'applications Scientifique S.A.Sustained release drug formulations
    US-5108758-AApril 28, 1992National Research Development CorporationDelayed release formulations
    US-5192741-AMarch 09, 1993Debiopharm S.A.Sustained and controlled release of water insoluble polypeptides
    WO-2013138352-A1September 19, 2013Synergy Pharmaceuticals Inc.Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation
    US-2006019347-A1January 26, 2006Ambrx, Inc.Biosynthetic polypeptides utilizing non-naturally encoded amino acids
    WO-0238129-A2May 16, 2002Creative Peptides Sweden Ab, Gardner, RebeccaPreparations pharmaceutiques a action retardee
    WO-2015054649-A2April 16, 2015Synergy Pharmaceuticals, Inc.Agonistes de guanylate cyclase utiles pour le traitement de troubles induits par les opioïdes
    WO-2004112711-A2December 29, 2004Andrx Pharmaceuticals, LlcOral extended-release composition
    EP-0467389-A2January 22, 1992University Of Kentucky Research FoundationDrug delivery system involving interaction between protein or polypeptide and hydrophobic biodegradable polymer
    US-2003082575-A1May 01, 2003The Scripps Research InstituteIn vivo incorporation of unnatural amino acids
    US-6531152-B1March 11, 2003Dexcel Pharma Technologies Ltd.Immediate release gastrointestinal drug delivery system
    WO-2012118972-A2September 07, 2012Synegy Pharmaceuticals Inc.Process of preparing guanylate cyclase c agonists
    WO-2014151206-A1September 25, 2014Synergy Pharmaceuticals Inc.Agonists of guanylate cyclase and their uses
    WO-2004019872-A2March 11, 2004Biorexis Pharmaceutical CorporationDelivrance orale de proteines hybrides modifiees de la transferrine
    WO-02072033-A2September 19, 2002Penwest Pharmaceuticals Co.Formes pharmaceutiques chronotherapeutiques contenant un glucocorticosteroide
    WO-2005030182-A1April 07, 2005Alza CorporationFormulations a liberation commandee presentant un taux croisssant de liberation
    WO-02072034-A2September 19, 2002Penwest Phamaceuticals Co.Chronotherapeutic dosage forms
    US-2003171296-A1September 11, 2003Praecis Pharmaceuticals, Inc.Pharmaceutical formulations for sustained drug delivery
    WO-03007913-A2January 30, 2003Samir Mitragotri, Zancong ShenMethod for oral drug delivery
    US-4767628-B1July 17, 1990Ici Plc
    US-2003108885-A1June 12, 2003The Scripps Research InstituteMethods and compositions for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs
    WO-03035041-A1May 01, 2003Depomed, Inc.Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
    WO-0112233-A2February 22, 2001Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.Formulation de peptide a liberation lente
    WO-9813029-A1April 02, 1998Duphar International Research B.V.Oral delayed immediate release formulation and method of preparation therefor
    WO-03075887-A1September 18, 2003Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S.Preparations medicamenteuses a liberation soutenue renfermant un peptide support
    US-4668506-AMay 26, 1987Bausch & Lomb IncorporatedSustained-release formulation containing and amino acid polymer
    US-2003138488-A1July 24, 2003Kohn Joachim B, Schachter Deborah MPharmaceutical formulation for regulating the timed release of biologically active compounds based on a polymer matrix
    WO-0149249-A2July 12, 2001Rutgers, The State UniversityFormulation pharmaceutique destinee a reguler la liberation dans le temps de composes biologiquement actifs a base d'une matrice polymere
    WO-03105812-A1December 24, 2003Euro-Celtique S.A.Systeme d'administration de medicaments contre la retention gastrique comprenant un polymere extrude hydratable
    US-2003068384-A1April 10, 2003Stephen Brocchini, Hanson Stephen R., Kohn Joachim B.Polymeric drug formulations
    US-4931279-AJune 05, 1990Bausch & Lomb IncorporatedSustained release formulation containing an ion-exchange resin
    WO-0243767-A1June 06, 2002Unigene Laboratories Inc.Apport oral ameliore de peptides au moyen de translocateurs de membrane pouvant etre coupes par une enzyme
    US-4713244-ADecember 15, 1987Bausch & Lomb IncorporatedSustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
    US-4910021-AMarch 20, 1990R. P. Scherer CorporationTargeted enternal delivery system
    US-5175003-ADecember 29, 1992Biosytes Usa, Inc.Dual mechanism controlled release system for drug dosage forms
    US-2003064105-A1April 03, 2003Myung-Jin Kim, Sun-Jin Kim, Kyu-Chan Kwon, Joon KimLipophilic-coated microparticle containing a protein drug and formulation comprising same
    WO-2015054500-A2April 16, 2015Synergy Pharmaceuticals, Inc.Agonistes de guanylate cyclase utiles pour la régulation négative de cytokines pro-inflammatoires
    US-2003216307-A1November 20, 2003Kohn Joachim B, Schachter Deborah MPharmaceutical formulation composed of a polymer blend and an active compound for time-controlled release
    WO-02072075-A1September 19, 2002Unigene Laboratories Inc.Oral peptide pharmaceutical dosage form and method of production
    US-2002019446-A1February 14, 2002Stephen Brocchini, Stephen R. Hanson, Joachim B. KohnPolymeric drug formulations
    JP-H10324642-ADecember 08, 1998Meiji Seika Kaisha Ltd, 明治製菓株式会社Colic delivery composite
    WO-02058672-A2August 01, 2002Debio Recherche Pharmaceutique S.A.Microparticles of biodegradable polymer encapsulating a biologically active substance
    WO-2004052339-A1June 24, 2004Salvona LlcPh triggered targeted controlled release systems
    WO-0230398-A2April 18, 2002Euro-Celtique S.A.Delayed release pharmaceutical formulations
    WO-02074247-A2September 26, 2002Praecis Pharmaceuticals IncorporatedFormulations pharmaceutiques a liberation prolongee
    US-2002176841-A1November 28, 2002Praecis Pharmaceuticals Inc.Pharmaceutical formulations for sustained release

NO-Patent Citations (15)

    Title
    ; BRADY ET AL., NATURE, vol. 368, 1994, pages 692 - 693
    BODANSKY; BODANSKY: "The Practice of Peptide Synthesis, 2nd ed.", 1994, SPRINGER VERLAG
    DEGRADO, ADV PROTEIN CHEM,, vol. 39, 1988, pages 51 - 124
    DELIE; BLANCO-PRIETO, MOLECULE, vol. 10, 2005, pages 65 - 80
    GROSS AND MEIENHOFER: "The Peptides: Analysis, Synthesis, Biology", vol. 1-4, 1979, ACADEMIC PRESS
    HUNT ET AL., INT JPEPT PROTEIN RES, vol. 42, 1993, pages 249
    HUNT: "The Non-Protein Amino Acids: In Chemistry and Biochemistry of the Amino Acids", 1985, CHAPMAN AND HALL
    JAMESON ET AL., NATURE, vol. 368, 1994, pages 744 - 746
    KOLODZIEJ ET AL., INT J PEPT PROTEIN RES, vol. 48, 1996, pages 274
    KUNWAR SHAILUBHAI: "Plecanatide and dolcanatide, novel guanylate cyclase-C agonists, ameliorate gastrointestinal inflammation in experimental models of murine colitis", WORLD JOURNAL OF GASTROINTESTINAL PHARMACOLOGY AND THERAPEUTICS, vol. 6, no. 4, 1 January 2015 (2015-01-01), pages 213, XP055350621, ISSN: 2150-5349, DOI: 10.4292/wjgpt.v6.i4.213
    LEDU ET AL., PROC NAT'L ACAD. SCI., vol. 100, 2003, pages 11263 - 78
    MERRIFIELD ET AL., J. AM. CHEM. SOC., vol. 85, 1963, pages 2149
    SAMSON ET AL., ENDOCRINOLOGY, vol. 137, 1996, pages 5182 - 5185
    SMITH ET AL., J MED CHEM, vol. 2 1, 1978, pages 117
    SOLTERO ET AL., INNOVATIONS IN PHARMACEUTICAL TECHNOLOGY, 2001, pages 106 - 110

Cited By (0)

    Publication numberPublication dateAssigneeTitle